Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Sun Pharmaceutical has agreed to acquire Checkpoint Therapeutics for an aggregate consideration of up to $355m upfront.

Both drugs are JAK 1/2 inhibitors and have been cleared for use in adults with severe hair loss caused by the condition. Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming ...

Both drugs are already approved in the US ... sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata.

Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...

Leqselvi is now FDA approved for treating severe alopecia areata. Sun Pharma added the oral drug to its pipeline via the $576 million acquisition of Concert Pharmaceuticals last year. Sun ...

These include slower-than-expected sales pick-up for key specialty brands, further delays in the launch of Leqselvi ... inhibitor drugs, which compete with Sun’s Ilumya brand, reported strong ...